Clinical Trials Logo

Virus Diseases clinical trials

View clinical trials related to Virus Diseases.

Filter by:

NCT ID: NCT04532411 Completed - Covid19 Clinical Trials

COVID-19 Testing Sample Acquisition Throughput and Efficiency

HexapodBooth
Start date: March 1, 2020
Phase:
Study type: Observational

This QI project seeks to evaluate the relative test sample acquisition throughput, personal protective equipment utilization, and relative operational costs of provider-administered COVID-19 (SARS-CoV-2) nasal samples with and with the use of HEPA-filtered, positive pressure isolation booths.

NCT ID: NCT04531735 Active, not recruiting - Covid19 Clinical Trials

Respiratory Syncytial Virus Infection May be More Dangerous in Neonate

Start date: March 1, 2020
Phase:
Study type: Observational

Investigators aimed to compare clinical and radiographic markers between SARS-CoV-2 positive and RSV positive infants

NCT ID: NCT04528719 Active, not recruiting - Clinical trials for Respiratory Syncytial Virus

A Dose Escalation Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1345 in Healthy Adults and in Children Who Are Respiratory Syncytial Virus (RSV)-Seropositive

Start date: September 30, 2020
Phase: Phase 1
Study type: Interventional

The primary objectives of this study are to evaluate the tolerability and reactogenicity of a single injection of up to 5 dose levels of mRNA-1345 in younger adults, women of child-bearing potential, and older adults including Japanese older adults; of 3 injections of the middle dose level of mRNA-1345 given 56 days apart in younger adults; of a booster injection of mRNA-1345 given approximately 12 months after the primary injection in older adults; and of 3 injections of 1 of 2 dose levels of mRNA-1345 given 56 days apart in children who are RSV-seropositive.

NCT ID: NCT04525456 Completed - Viral Infection Clinical Trials

Immune Responses With Reduxium

Start date: October 7, 2020
Phase: N/A
Study type: Interventional

Reduxium is a dietary supplement that provides immune support. This natural compound is orally-ingested in the form of droplets in water to boost the immune system and control inflammation. There is not enough data on the mechanism associated with the action of Reduxium or the extent of the immune response increase it produces. In this study, the investigators propose treating a group of healthy volunteers with Reduxium and investigate the utility of this approach in boosting the native and adaptive immune responses that correlate with immune protection. This may form the basis for a future study employing the product in infectious disease patients.

NCT ID: NCT04523246 Completed - Clinical trials for Corona Virus Infection

Training the Innate Immune System Against SARS-CoV-2 (COVID-19) Using the Shingrix Vaccine in Nursing Home Residents

NH-Shingrix
Start date: September 1, 2020
Phase: Early Phase 1
Study type: Interventional

The purpose of this study is to measure the effect of the Shingrix vaccine on your immune system and whether that has any effect on the body's ability to fight off other infections such as COVID-19. We hypothesize that: H1: Shingrix vaccination will elevate acute and trained immunity H2: For 6 months following the first injection, increased levels of acute and trained immunity is associated with less disease, including fewer hospitalizations and deaths associated with flu, pneumonia, and COVID-19.

NCT ID: NCT04519307 Active, not recruiting - Viral Infection Clinical Trials

Evaluation of Newborns Presenting With Suspected COVID 19

Start date: March 1, 2020
Phase:
Study type: Observational

This study evaluates the newborns who had respiratory symptoms at the neonatal intensive care admission

NCT ID: NCT04507802 Not yet recruiting - Clinical trials for Acute Respiratory Distress Syndrome

Helmet vs Face Mask in Patients With Acute Respiratory Distress Syndrome

Start date: August 2020
Phase: N/A
Study type: Interventional

The objective of this study is to evaluate the efficacy of noninvasive ventilation with helmet in reducing endotracheal intubation rates in comparison with Noninvasive Ventilation (NIV) facemask among patients with Acute Respiratory Distress Syndrome (ARDS)

NCT ID: NCT04496245 Completed - Covid19 Clinical Trials

Reducing Acute Severe Respiratory Events in Health Care Workers During the Covid-19 Pandemic With OM85

COVIDRASP
Start date: August 24, 2020
Phase: Phase 3
Study type: Interventional

Parallel group, Wait-list design, with treatment delayed for 3 months. Participants will be randomized on a 1:1 ratio with 500 participants per group in Australia. Group 1: Wait-list control. One capsule OM85 (7.0 mg) will be given daily for 3 months, commencing in Month 3, with 3 months follow-up off treatment. Group 2: Initial treatment. One capsule OM85 (7.0 mg) will be given daily for 3 months, commencing on day 0, with 3 months follow-up off treatment.

NCT ID: NCT04494204 Completed - Clinical trials for Treatment of Covid-19 Virus Infection

Effect of a Combination of Treatment of Reginmune Capsule and Immunofree Tablets in the Treatment of Mild to Moderate COVID-19 Patients

Start date: August 7, 2020
Phase: Phase 2/Phase 3
Study type: Interventional

While novel drug discovery and vaccine studies are time taking process, re-purposing old drugs against the COVID-2019 epidemic can help identify treatments, with known pre-clinical, pharmacokinetic, pharmacodynamic, and toxicity profiles, which can rapidly enter Phase 3 or 4 or can be used directly in clinical settings. Immunofree has many of the herbs which have been evaluated by other trials published for Covid-19 treatment. The Immunofree tablet of the test product is an Ayurvedic proprietary medicine and is a combination of polyherbal mixture. The components of this formulation are known for their anti-viral and immunomodulatory effects. Also, Reginmune, owing to its immunomodulatory effect might help in easing the symptoms and decrease the viral load.

NCT ID: NCT04483518 Completed - Clinical trials for Observe and Describe the Prevalence of Hepatitis D Infection Among HBsAg Positive People

Epidemiological Survey of Hepatitis D Virus Infection in China

Start date: June 3, 2019
Phase:
Study type: Observational

This cross-sectional study will screen out hepatitis D virus-infected patients in HBsAg-positive people. Observe and describe the prevalence of hepatitis D infection among HBsAg positive people. The provinces of China are divided into 5 geographical areas (North, South, East, West and Central) to recruit patients according to the population density of each area. After statistical calculation, the total number of population needed is 3808.